Umecrine Cognition gets two US patent Notices of Allowance for second-generation GAMSA
Umecrine Cognition said it received two Notices of Allowance from the USPTO for patent applications covering two second-generation substances in the same GAMSA drug class as its current program.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.